Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Barr Plan B "Not Approvable" Switch Decision Puts CDER Director In Hot Seat

This article was originally published in The Pink Sheet Daily

Executive Summary

CDER Acting Director Galson takes full responsibility for "not approvable" action; says he did not consider outside pressure in making his decision. "Not approvable" letter issued because the data were not "adequate" for the "next level up."

You may also be interested in...



Plan B OTC Submission Deemed "Not Approvable"

Barr will have to detail a mechanism for drugstores to screen women less than 16 years of age for nonprescription use of the emergency contraceptive. FDA's decision goes against the recommendation of its advisory panels.

Energy & Commerce Committee Closely Monitors First Post-McClellan ODAC Meeting

Rep. Deutsch and Energy & Commerce Committee staffers get first row reserved seat at May 3 Genta’s Genasense and Allos’ Excelar meeting. Meeting serves as the litmus test for concerns that agency review process will “revert” to overregulation by FDA in post-Commissioner McClellan period.

Pazdur’s Big Moment: ‘Project Odyssey’ Webinar Gives Oncology Chief External Buy-In On His Ideas To Revamp ODAC

OCE Director Richard Pazdur is known for cultivating 'Pazdur moments' during advisory committees when he feels the conversation has gone off track. A recent webinar with ODAC members created a perfect opportunity to promote his agenda.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS059610

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel